Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Aura Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216808
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(33,685) | $(27,483) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 274 | 291 |
| Accretion income on marketable securities | (292) | (501) |
| Stock-based compensation expense | 3,824 | 3,514 |
| Other non-cash items | — | 27 |
| Non-cash lease expense | 412 | 374 |
Item 1. Financial Statements.
FAQ
- What is Aura Biosciences, Inc.'s D&A?
- Aura Biosciences, Inc. (AURA) reported D&A of $274K in Q1 2026.
- How has Aura Biosciences, Inc.'s D&A changed year-over-year?
- Aura Biosciences, Inc.'s D&A decreased by 5.8% year-over-year, from $291K to $274K.
- What is the long-term trend for Aura Biosciences, Inc.'s D&A?
- Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s D&A has grown at a 9.3% compound annual growth rate (CAGR), from $815K to $1.16M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Aura Biosciences, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude